Moderna, Inc. (NASDAQ: MRNA) Stock Competitors & Peer Comparison
See MRNA's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for MRNA and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MRNA | $223.37 | -3.45% | 90.4B | -27.41 | -$8.15 | N/A |
| VRTX | $538.60 | -0.74% | 136.6B | 28.30 | $19.03 | N/A |
| REGN | $955.47 | +0.45% | 98.8B | 20.94 | $45.63 | +0.38% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $960.04 | -2.17% | 60B | 34.62 | $27.73 | N/A |
| ONC | $416.54 | +0.14% | 44.5B | 73.33 | $5.68 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $172.29 | -2.30% | 37.3B | -19.53 | -$8.82 | N/A |
| RVMDW | $7.68 | -5.83% | 35.9B | -0.87 | -$8.82 | N/A |
| GMAB | $51.37 | -0.72% | 31.7B | 38.71 | $1.33 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
MRNA vs VRTX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, VRTX has a market cap of 136.6B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while VRTX trades at $538.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas VRTX's P/E ratio is 28.30. In terms of profitability, MRNA's ROE is -0.38%, compared to VRTX's ROE of +0.20%. Regarding short-term risk, MRNA is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
MRNA vs REGN Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, REGN has a market cap of 98.8B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while REGN trades at $955.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas REGN's P/E ratio is 20.94. In terms of profitability, MRNA's ROE is -0.38%, compared to REGN's ROE of +0.15%. Regarding short-term risk, MRNA is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
MRNA vs VRNA Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas VRNA's P/E ratio is -102.80. In terms of profitability, MRNA's ROE is -0.38%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, MRNA is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
MRNA vs ARGX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ARGX has a market cap of 60B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ARGX trades at $960.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ARGX's P/E ratio is 34.62. In terms of profitability, MRNA's ROE is -0.38%, compared to ARGX's ROE of +0.17%. Regarding short-term risk, MRNA is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check ARGX's competition here
BeOne Medicines AG (NASDAQ: ONC)
MRNA vs ONC Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ONC has a market cap of 44.5B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ONC trades at $416.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ONC's P/E ratio is 73.33. In terms of profitability, MRNA's ROE is -0.38%, compared to ONC's ROE of +0.18%. Regarding short-term risk, MRNA is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check ONC's competition here
Seagen Inc. (NASDAQ: SGEN)
MRNA vs SGEN Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MRNA's ROE is -0.38%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MRNA is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
MRNA vs RVMD Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, RVMD has a market cap of 37.3B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while RVMD trades at $172.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas RVMD's P/E ratio is -19.53. In terms of profitability, MRNA's ROE is -0.38%, compared to RVMD's ROE of -0.92%. Regarding short-term risk, MRNA is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
MRNA vs RVMDW Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, RVMDW has a market cap of 35.9B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while RVMDW trades at $7.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas RVMDW's P/E ratio is -0.87. In terms of profitability, MRNA's ROE is -0.38%, compared to RVMDW's ROE of -0.92%. Regarding short-term risk, MRNA is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check RVMDW's competition here
Genmab A/S (NASDAQ: GMAB)
MRNA vs GMAB Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, GMAB has a market cap of 31.7B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while GMAB trades at $51.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas GMAB's P/E ratio is 38.71. In terms of profitability, MRNA's ROE is -0.38%, compared to GMAB's ROE of +0.12%. Regarding short-term risk, MRNA is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check GMAB's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
MRNA vs ROIV Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ROIV has a market cap of 28.6B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ROIV trades at $39.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ROIV's P/E ratio is -37.61. In terms of profitability, MRNA's ROE is -0.38%, compared to ROIV's ROE of -0.08%. Regarding short-term risk, MRNA is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
MRNA vs INSM Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, INSM has a market cap of 26.6B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while INSM trades at $121.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas INSM's P/E ratio is -42.96. In terms of profitability, MRNA's ROE is -0.38%, compared to INSM's ROE of -0.83%. Regarding short-term risk, MRNA is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check INSM's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
MRNA vs UTHR Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, UTHR has a market cap of 25.2B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while UTHR trades at $591.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas UTHR's P/E ratio is 21.15. In terms of profitability, MRNA's ROE is -0.38%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, MRNA is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check UTHR's competition here
Incyte Corporation (NASDAQ: INCY)
MRNA vs INCY Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, INCY has a market cap of 24.7B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while INCY trades at $120.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas INCY's P/E ratio is 16.26. In terms of profitability, MRNA's ROE is -0.38%, compared to INCY's ROE of +0.07%. Regarding short-term risk, MRNA is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check INCY's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
MRNA vs ALNY Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ALNY has a market cap of 22.1B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ALNY trades at $165.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ALNY's P/E ratio is 8.34. In terms of profitability, MRNA's ROE is -0.38%, compared to ALNY's ROE of +1.60%. Regarding short-term risk, MRNA is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
MRNA vs BNTX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, BNTX has a market cap of 21.2B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while BNTX trades at $85.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas BNTX's P/E ratio is -11.10. In terms of profitability, MRNA's ROE is -0.38%, compared to BNTX's ROE of -0.08%. Regarding short-term risk, MRNA is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check BNTX's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
MRNA vs BGNE Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MRNA's ROE is -0.38%, compared to BGNE's ROE of +0.18%. Regarding short-term risk, MRNA is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
MRNA vs DNA-WT Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MRNA's ROE is -0.38%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, MRNA is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check DNA-WT's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
MRNA vs ASND Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ASND has a market cap of 18.1B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ASND trades at $275.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ASND's P/E ratio is -113.80. In terms of profitability, MRNA's ROE is -0.38%, compared to ASND's ROE of +1.08%. Regarding short-term risk, MRNA is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
MRNA vs EXEL Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, EXEL has a market cap of 17.3B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while EXEL trades at $69.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas EXEL's P/E ratio is 19.71. In terms of profitability, MRNA's ROE is -0.38%, compared to EXEL's ROE of +0.46%. Regarding short-term risk, MRNA is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
MRNA vs NBIX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, NBIX has a market cap of 16.9B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while NBIX trades at $167.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas NBIX's P/E ratio is 24.19. In terms of profitability, MRNA's ROE is -0.38%, compared to NBIX's ROE of +0.20%. Regarding short-term risk, MRNA is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
MRNA vs JAZZ Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, JAZZ has a market cap of 15.5B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while JAZZ trades at $241.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas JAZZ's P/E ratio is 9.01. In terms of profitability, MRNA's ROE is -0.38%, compared to JAZZ's ROE of +0.05%. Regarding short-term risk, MRNA is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
MRNA vs BBIO Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, BBIO has a market cap of 15.3B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while BBIO trades at $78.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas BBIO's P/E ratio is -25.76. In terms of profitability, MRNA's ROE is -0.38%, compared to BBIO's ROE of +0.27%. Regarding short-term risk, MRNA is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
MRNA vs KRTX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MRNA's ROE is -0.38%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MRNA is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check KRTX's competition here
Bio-Techne Corporation (NASDAQ: TECH)
MRNA vs TECH Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, TECH has a market cap of 11.4B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while TECH trades at $72.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas TECH's P/E ratio is 37.53. In terms of profitability, MRNA's ROE is -0.38%, compared to TECH's ROE of +0.08%. Regarding short-term risk, MRNA is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check TECH's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
MRNA vs HALO Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, HALO has a market cap of 11.4B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while HALO trades at $100.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas HALO's P/E ratio is 18.71. In terms of profitability, MRNA's ROE is -0.38%, compared to HALO's ROE of +5.44%. Regarding short-term risk, MRNA is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check HALO's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
MRNA vs SMMT Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, SMMT has a market cap of 11.3B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while SMMT trades at $14.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas SMMT's P/E ratio is -12.63. In terms of profitability, MRNA's ROE is -0.38%, compared to SMMT's ROE of -1.39%. Regarding short-term risk, MRNA is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check SMMT's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
MRNA vs RNAM Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas RNAM's P/E ratio is -17.39. In terms of profitability, MRNA's ROE is -0.38%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, MRNA is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check RNAM's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
MRNA vs BMRN Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while BMRN trades at $57.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas BMRN's P/E ratio is 27.51. In terms of profitability, MRNA's ROE is -0.38%, compared to BMRN's ROE of -0.00%. Regarding short-term risk, MRNA is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check BMRN's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
MRNA vs KYMR Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, KYMR has a market cap of 10.9B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while KYMR trades at $127.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas KYMR's P/E ratio is -35.24. In terms of profitability, MRNA's ROE is -0.38%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, MRNA is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check KYMR's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
MRNA vs PCVX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, PCVX has a market cap of 10B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while PCVX trades at $63.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas PCVX's P/E ratio is -8.31. In terms of profitability, MRNA's ROE is -0.38%, compared to PCVX's ROE of -0.42%. Regarding short-term risk, MRNA is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check PCVX's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
MRNA vs MDGL Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, MDGL has a market cap of 9.9B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while MDGL trades at $427.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas MDGL's P/E ratio is -33.39. In terms of profitability, MRNA's ROE is -0.38%, compared to MDGL's ROE of -0.27%. Regarding short-term risk, MRNA is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check MDGL's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
MRNA vs SYRE Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, SYRE has a market cap of 9.9B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while SYRE trades at $104.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas SYRE's P/E ratio is -53.33. In terms of profitability, MRNA's ROE is -0.38%, compared to SYRE's ROE of -0.30%. Regarding short-term risk, MRNA is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check SYRE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
MRNA vs TGTX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, TGTX has a market cap of 9.8B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while TGTX trades at $64.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas TGTX's P/E ratio is 23.37. In terms of profitability, MRNA's ROE is -0.38%, compared to TGTX's ROE of +0.18%. Regarding short-term risk, MRNA is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check TGTX's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
MRNA vs RXDX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MRNA's ROE is -0.38%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MRNA is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check RXDX's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
MRNA vs PRAX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, PRAX has a market cap of 9.2B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while PRAX trades at $328.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas PRAX's P/E ratio is -25.38. In terms of profitability, MRNA's ROE is -0.38%, compared to PRAX's ROE of -0.29%. Regarding short-term risk, MRNA is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check PRAX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
MRNA vs NUVL Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas NUVL's P/E ratio is -21.79. In terms of profitability, MRNA's ROE is -0.38%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, MRNA is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check NUVL's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
MRNA vs KRYS Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, KRYS has a market cap of 9B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while KRYS trades at $305.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas KRYS's P/E ratio is 38.25. In terms of profitability, MRNA's ROE is -0.38%, compared to KRYS's ROE of +0.17%. Regarding short-term risk, MRNA is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check KRYS's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
MRNA vs CRNX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas CRNX's P/E ratio is -16.86. In terms of profitability, MRNA's ROE is -0.38%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, MRNA is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check CRNX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
MRNA vs IMGN Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MRNA's ROE is -0.38%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, MRNA is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check IMGN's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
MRNA vs PTGX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, PTGX has a market cap of 8.5B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while PTGX trades at $130.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas PTGX's P/E ratio is 127.14. In terms of profitability, MRNA's ROE is -0.38%, compared to PTGX's ROE of +0.43%. Regarding short-term risk, MRNA is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check PTGX's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
MRNA vs APGE Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas APGE's P/E ratio is -31.19. In terms of profitability, MRNA's ROE is -0.38%, compared to APGE's ROE of -0.30%. Regarding short-term risk, MRNA is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
MRNA vs BPMC Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MRNA's ROE is -0.38%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, MRNA is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
MRNA vs CERE Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas CERE's P/E ratio is -16.47. In terms of profitability, MRNA's ROE is -0.38%, compared to CERE's ROE of -0.72%. Regarding short-term risk, MRNA is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check CERE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
MRNA vs RYTM Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, RYTM has a market cap of 8B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while RYTM trades at $115.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas RYTM's P/E ratio is -36.98. In terms of profitability, MRNA's ROE is -0.38%, compared to RYTM's ROE of -0.84%. Regarding short-term risk, MRNA is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check RYTM's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
MRNA vs CYTK Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, CYTK has a market cap of 7.8B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while CYTK trades at $56.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas CYTK's P/E ratio is -7.77. In terms of profitability, MRNA's ROE is -0.38%, compared to CYTK's ROE of +1.57%. Regarding short-term risk, MRNA is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check CYTK's competition here
Abivax S.A. (NASDAQ: ABVX)
MRNA vs ABVX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ABVX has a market cap of 7.5B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ABVX trades at $87.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ABVX's P/E ratio is -14.35. In terms of profitability, MRNA's ROE is -0.38%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, MRNA is similarly volatile compared to ABVX. This indicates similar risk in terms of short-term price fluctuations for MRNA.Check ABVX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
MRNA vs AXSM Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, AXSM has a market cap of 7.5B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while AXSM trades at $141.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas AXSM's P/E ratio is -36.99. In terms of profitability, MRNA's ROE is -0.38%, compared to AXSM's ROE of -1.90%. Regarding short-term risk, MRNA is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check AXSM's competition here
Metsera, Inc. (NASDAQ: MTSR)
MRNA vs MTSR Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas MTSR's P/E ratio is -23.58. In terms of profitability, MRNA's ROE is -0.38%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, MRNA is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check MTSR's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
MRNA vs TWST Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, TWST has a market cap of 7.3B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while TWST trades at $111.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas TWST's P/E ratio is -50.27. In terms of profitability, MRNA's ROE is -0.38%, compared to TWST's ROE of -0.23%. Regarding short-term risk, MRNA is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check TWST's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
MRNA vs ORKA Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ORKA has a market cap of 7.1B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ORKA trades at $105.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ORKA's P/E ratio is -54.30. In terms of profitability, MRNA's ROE is -0.38%, compared to ORKA's ROE of -0.19%. Regarding short-term risk, MRNA is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check ORKA's competition here
Immunovant, Inc. (NASDAQ: IMVT)
MRNA vs IMVT Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, IMVT has a market cap of 7.1B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while IMVT trades at $34.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas IMVT's P/E ratio is -12.12. In terms of profitability, MRNA's ROE is -0.38%, compared to IMVT's ROE of -0.63%. Regarding short-term risk, MRNA is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check IMVT's competition here
10x Genomics, Inc. (NASDAQ: TXG)
MRNA vs TXG Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, TXG has a market cap of 7B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while TXG trades at $58.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas TXG's P/E ratio is -98.63. In terms of profitability, MRNA's ROE is -0.38%, compared to TXG's ROE of -0.08%. Regarding short-term risk, MRNA is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check TXG's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
MRNA vs KOD Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, KOD has a market cap of 7B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while KOD trades at $111.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas KOD's P/E ratio is -26.66. In terms of profitability, MRNA's ROE is -0.38%, compared to KOD's ROE of -2.88%. Regarding short-term risk, MRNA is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check KOD's competition here
Merus N.V. (NASDAQ: MRUS)
MRNA vs MRUS Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas MRUS's P/E ratio is -17.05. In terms of profitability, MRNA's ROE is -0.38%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, MRNA is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check MRUS's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
MRNA vs ARWR Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ARWR has a market cap of 6.7B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ARWR trades at $47.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ARWR's P/E ratio is -21.24. In terms of profitability, MRNA's ROE is -0.38%, compared to ARWR's ROE of -0.75%. Regarding short-term risk, MRNA is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check ARWR's competition here
Arcellx, Inc. (NASDAQ: ACLX)
MRNA vs ACLX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ACLX's P/E ratio is -28.27. In terms of profitability, MRNA's ROE is -0.38%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, MRNA is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check ACLX's competition here
CG Oncology Inc. (NASDAQ: CGON)
MRNA vs CGON Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, CGON has a market cap of 6.6B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while CGON trades at $74.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas CGON's P/E ratio is -27.66. In terms of profitability, MRNA's ROE is -0.38%, compared to CGON's ROE of -0.25%. Regarding short-term risk, MRNA is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check CGON's competition here
Belite Bio, Inc (NASDAQ: BLTE)
MRNA vs BLTE Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, BLTE has a market cap of 6.6B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while BLTE trades at $164.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas BLTE's P/E ratio is -87.89. In terms of profitability, MRNA's ROE is -0.38%, compared to BLTE's ROE of -0.17%. Regarding short-term risk, MRNA is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check BLTE's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
MRNA vs CAI Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, CAI has a market cap of 6.6B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while CAI trades at $23.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas CAI's P/E ratio is 64.74. In terms of profitability, MRNA's ROE is -0.38%, compared to CAI's ROE of +0.16%. Regarding short-term risk, MRNA is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check CAI's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
MRNA vs RETA Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas RETA's P/E ratio is -66.29. In terms of profitability, MRNA's ROE is -0.38%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MRNA is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check RETA's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
MRNA vs IBRX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, IBRX has a market cap of 6.4B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while IBRX trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas IBRX's P/E ratio is -6.21. In terms of profitability, MRNA's ROE is -0.38%, compared to IBRX's ROE of +1.25%. Regarding short-term risk, MRNA is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check IBRX's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
MRNA vs CNTA Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas CNTA's P/E ratio is -22.63. In terms of profitability, MRNA's ROE is -0.38%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, MRNA is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check CNTA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
MRNA vs LGND Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, LGND has a market cap of 6.2B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while LGND trades at $308.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas LGND's P/E ratio is 33.90. In terms of profitability, MRNA's ROE is -0.38%, compared to LGND's ROE of +0.05%. Regarding short-term risk, MRNA is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check LGND's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
MRNA vs MIRM Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, MIRM has a market cap of 6.1B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while MIRM trades at $93.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas MIRM's P/E ratio is -6.46. In terms of profitability, MRNA's ROE is -0.38%, compared to MIRM's ROE of -7.34%. Regarding short-term risk, MRNA is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check MIRM's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
MRNA vs TERN Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, TERN has a market cap of 6.1B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas TERN's P/E ratio is -51.41. In terms of profitability, MRNA's ROE is -0.38%, compared to TERN's ROE of -0.14%. Regarding short-term risk, MRNA is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check TERN's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
MRNA vs CDTX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas CDTX's P/E ratio is -19.77. In terms of profitability, MRNA's ROE is -0.38%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, MRNA is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
MRNA vs ABCM Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MRNA's ROE is -0.38%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MRNA is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
MRNA vs ISEE Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MRNA's ROE is -0.38%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MRNA is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check ISEE's competition here
Erasca, Inc. (NASDAQ: ERAS)
MRNA vs ERAS Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ERAS has a market cap of 5.5B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ERAS trades at $15.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ERAS's P/E ratio is -16.84. In terms of profitability, MRNA's ROE is -0.38%, compared to ERAS's ROE of -0.62%. Regarding short-term risk, MRNA is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check ERAS's competition here
Veradermics, Incorporated (NYSE: MANE)
MRNA vs MANE Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, MANE has a market cap of 5.5B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while MANE trades at $129.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas MANE's P/E ratio is -41.27. In terms of profitability, MRNA's ROE is -0.38%, compared to MANE's ROE of -0.20%. Regarding short-term risk, MRNA is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check MANE's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
MRNA vs PTCT Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, PTCT has a market cap of 5.3B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while PTCT trades at $63.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas PTCT's P/E ratio is -45.35. In terms of profitability, MRNA's ROE is -0.38%, compared to PTCT's ROE of +0.57%. Regarding short-term risk, MRNA is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check PTCT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
MRNA vs SRRK Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, SRRK has a market cap of 5.3B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while SRRK trades at $43.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas SRRK's P/E ratio is -12.52. In terms of profitability, MRNA's ROE is -0.38%, compared to SRRK's ROE of -1.75%. Regarding short-term risk, MRNA is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check SRRK's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
MRNA vs APLS Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas APLS's P/E ratio is 38.35. In terms of profitability, MRNA's ROE is -0.38%, compared to APLS's ROE of +0.40%. Regarding short-term risk, MRNA is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check APLS's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
MRNA vs DNTH Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, DNTH has a market cap of 5.2B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while DNTH trades at $91.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas DNTH's P/E ratio is -22.12. In terms of profitability, MRNA's ROE is -0.38%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, MRNA is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
MRNA vs COGT Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, COGT has a market cap of 5B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while COGT trades at $28.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas COGT's P/E ratio is -13.54. In terms of profitability, MRNA's ROE is -0.38%, compared to COGT's ROE of -0.71%. Regarding short-term risk, MRNA is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check COGT's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
MRNA vs EWTX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, EWTX has a market cap of 4.9B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while EWTX trades at $45.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas EWTX's P/E ratio is -24.83. In terms of profitability, MRNA's ROE is -0.38%, compared to EWTX's ROE of +1.30%. Regarding short-term risk, MRNA is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check EWTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
MRNA vs TVTX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, TVTX has a market cap of 4.9B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while TVTX trades at $50.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas TVTX's P/E ratio is -112.56. In terms of profitability, MRNA's ROE is -0.38%, compared to TVTX's ROE of -1.86%. Regarding short-term risk, MRNA is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check TVTX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
MRNA vs IONS Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, IONS has a market cap of 4.8B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while IONS trades at $29.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas IONS's P/E ratio is -8.89. In terms of profitability, MRNA's ROE is -0.38%, compared to IONS's ROE of -1.20%. Regarding short-term risk, MRNA is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check IONS's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
MRNA vs ADPT Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ADPT has a market cap of 4.7B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ADPT trades at $29.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ADPT's P/E ratio is -70.83. In terms of profitability, MRNA's ROE is -0.38%, compared to ADPT's ROE of -0.37%. Regarding short-term risk, MRNA is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check ADPT's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
MRNA vs FOLD Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas FOLD's P/E ratio is -161.00. In terms of profitability, MRNA's ROE is -0.38%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, MRNA is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
MRNA vs AKRO Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas AKRO's P/E ratio is -14.57. In terms of profitability, MRNA's ROE is -0.38%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, MRNA is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
MRNA vs ALPN Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MRNA's ROE is -0.38%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, MRNA is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check ALPN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
MRNA vs DFTX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, DFTX has a market cap of 4.4B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while DFTX trades at $32.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas DFTX's P/E ratio is N/A. In terms of profitability, MRNA's ROE is -0.38%, compared to DFTX's ROE of -0.54%. Regarding short-term risk, MRNA is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check DFTX's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
MRNA vs TNGX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, TNGX has a market cap of 4.3B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while TNGX trades at $25.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas TNGX's P/E ratio is -30.72. In terms of profitability, MRNA's ROE is -0.38%, compared to TNGX's ROE of -0.30%. Regarding short-term risk, MRNA is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check TNGX's competition here
Opthea Limited (NASDAQ: OPT)
MRNA vs OPT Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas OPT's P/E ratio is -1.52. In terms of profitability, MRNA's ROE is -0.38%, compared to OPT's ROE of +1.18%. Regarding short-term risk, MRNA is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
MRNA vs PRTC Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas PRTC's P/E ratio is -3.78. In terms of profitability, MRNA's ROE is -0.38%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, MRNA is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
MRNA vs MRTX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MRNA's ROE is -0.38%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MRNA is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check MRTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
MRNA vs CRSP Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, CRSP has a market cap of 4.1B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while CRSP trades at $42.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas CRSP's P/E ratio is -8.87. In terms of profitability, MRNA's ROE is -0.38%, compared to CRSP's ROE of -0.26%. Regarding short-term risk, MRNA is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check CRSP's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
MRNA vs RLAY Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while RLAY trades at $18.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas RLAY's P/E ratio is -11.52. In terms of profitability, MRNA's ROE is -0.38%, compared to RLAY's ROE of -0.40%. Regarding short-term risk, MRNA is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check RLAY's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
MRNA vs XENE Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, XENE has a market cap of 4B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while XENE trades at $40.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas XENE's P/E ratio is -8.61. In terms of profitability, MRNA's ROE is -0.38%, compared to XENE's ROE of -0.40%. Regarding short-term risk, MRNA is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check XENE's competition here
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS)
MRNA vs TARS Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, TARS has a market cap of 4B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while TARS trades at $80.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas TARS's P/E ratio is -73.65. In terms of profitability, MRNA's ROE is -0.38%, compared to TARS's ROE of -2.46%. Regarding short-term risk, MRNA is less volatile compared to TARS. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check TARS's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
MRNA vs AMLX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, AMLX has a market cap of 3.9B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while AMLX trades at $30.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas AMLX's P/E ratio is -20.19. In terms of profitability, MRNA's ROE is -0.38%, compared to AMLX's ROE of -0.42%. Regarding short-term risk, MRNA is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check AMLX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
MRNA vs CPRX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas CPRX's P/E ratio is 17.49. In terms of profitability, MRNA's ROE is -0.38%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, MRNA is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check CPRX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
MRNA vs ABCL Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ABCL has a market cap of 3.8B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ABCL trades at $11.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ABCL's P/E ratio is -21.28. In terms of profitability, MRNA's ROE is -0.38%, compared to ABCL's ROE of -0.15%. Regarding short-term risk, MRNA is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check ABCL's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
MRNA vs RYZB Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MRNA's ROE is -0.38%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MRNA is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
MRNA vs CBAY Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MRNA's ROE is -0.38%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MRNA is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for MRNA.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
MRNA vs VKTX Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while VKTX trades at $29.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas VKTX's P/E ratio is -5.41. In terms of profitability, MRNA's ROE is -0.38%, compared to VKTX's ROE of -1.17%. Regarding short-term risk, MRNA is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check VKTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
MRNA vs ELVN Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, ELVN has a market cap of 3.6B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while ELVN trades at $48.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas ELVN's P/E ratio is -29.22. In terms of profitability, MRNA's ROE is -0.38%, compared to ELVN's ROE of -0.17%. Regarding short-term risk, MRNA is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check ELVN's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
MRNA vs IOVA Comparison November 2026
Moderna, Inc. (NASDAQ: MRNA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MRNA stands at 90.4B. In comparison, IOVA has a market cap of 3.6B. Regarding current trading prices, MRNA is priced at $223.37 on the NASDAQ, while IOVA trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MRNA currently has a P/E ratio of -27.41, whereas IOVA's P/E ratio is -10.63. In terms of profitability, MRNA's ROE is -0.38%, compared to IOVA's ROE of -0.30%. Regarding short-term risk, MRNA is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for MRNA.Check IOVA's competition here